Figure 1.

Survival outcomes for patients treated with AZA and DEC. (A) Treatment with AZA and DEC did not result in a statistically significant difference in terms of median, 1-year, or 2-year OS from the date of randomization. (B-C) OS by clinical (B) and major genetic (C) subgroups; hazard ratios (HRs) with 95% confidence intervals (CIs) for various clinical (B) and major genetic (C) subgroups are shown. All CIs included the null effect, suggesting that survival outcomes were similar in all analyzed clinical (B) and major genetic (C) subgroups. BM, bone marrow; LCL, lower confidence limit; UCL, upper confidence limit; WBC, white blood cell.